John Orwin - Atreca CEO Pres
| BCELDelisted Stock | USD 1.04 0.02 1.89% |
Insider
John Orwin is CEO Pres of Atreca Inc
| Age | 59 |
| Phone | 650 595 2595 |
| Web | https://www.atreca.com |
Atreca Management Efficiency
The company has return on total asset (ROA) of (0.512) % which means that it has lost $0.512 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.827) %, meaning that it created substantial loss on money invested by shareholders. Atreca's management efficiency ratios could be used to measure how well Atreca manages its routine affairs as well as how well it operates its assets and liabilities.Atreca Inc currently holds 63.88 M in liabilities with Debt to Equity (D/E) ratio of 0.57, which is about average as compared to similar companies. Atreca Inc has a current ratio of 7.98, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Atreca until it has trouble settling it off, either with new capital or with free cash flow. So, Atreca's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Atreca Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Atreca to invest in growth at high rates of return. When we think about Atreca's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Path FRCP | Revolution Medicines | 61 | |
| Dawn Kalmar | Stoke Therapeutics | 46 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Michael Fischbach | Revolution Medicines | 43 | |
| Elizabeth Montgomery | Black Diamond Therapeutics | 52 | |
| David Pompliano | Revolution Medicines | N/A | |
| Desiree DDS | Passage Bio | N/A | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| Walter Reiher | Revolution Medicines | N/A | |
| MSc MBA | Passage Bio | 55 | |
| Marc MD | Alector | 50 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| FACC MD | Stoke Therapeutics | 61 | |
| Melanie Morrison | Black Diamond Therapeutics | 49 | |
| Sergey MD | Black Diamond Therapeutics | 55 | |
| David Epstein | Black Diamond Therapeutics | 65 | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| Fang PharmD | Black Diamond Therapeutics | 37 | |
| Michelle Corral | Alector | N/A | |
| Erica Jefferson | Alector | N/A | |
| Peter Heutink | Alector | N/A | |
Management Performance
| Return On Equity | -1.83 | |||
| Return On Asset | -0.51 |
Atreca Inc Leadership Team
Elected by the shareholders, the Atreca's board of directors comprises two types of representatives: Atreca inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atreca. The board's role is to monitor Atreca's management team and ensure that shareholders' interests are well served. Atreca's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atreca's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yann Tan, Chief Technologist | ||
| Herbert Cross, Chief Officer | ||
| Philippe MD, Chief Officer | ||
| Stephen Gould, Chief Officer | ||
| Rick Ruiz, Principal Officer | ||
| Tito Serafini, Founder Director | ||
| John MBA, CEO and Presidentident | ||
| John Orwin, CEO Pres | ||
| Courtney JD, General Secretary | ||
| Roger Ruiz, Vice Finance |
Atreca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Atreca a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.83 | |||
| Return On Asset | -0.51 | |||
| Current Valuation | (17.08 M) | |||
| Shares Outstanding | 38.41 M | |||
| Shares Owned By Insiders | 2.73 % | |||
| Shares Owned By Institutions | 24.54 % | |||
| Number Of Shares Shorted | 272.73 K | |||
| Price To Earning | (3.53) X | |||
| Price To Book | 0.28 X | |||
| EBITDA | (76.42 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Atreca Pink Sheet
If you are still planning to invest in Atreca Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Atreca's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |